Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Diamine Beta2 Adrenergic Receptor Agonists

a technology of adrenergic receptor and diamine beta2, which is applied in the field of 2 adrenergic receptor agonists, can solve the problems of shortening the duration of action of current agents, potency, selectivity, and/or onset, and achieves the effect of long duration of action

Inactive Publication Date: 2008-02-14
THERAVANCE BIOPHARMA R&D IP LLC
View PDF31 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0003] The invention provides novel compounds that possess β2 adrenergic receptor agonist activity. Among other properties, compounds of the invention are potent and selective β2 adrenergic receptor agonists. In addition, an exemplary compound of the invention has been demonstrated to possess a surprising and unexpectedly long duration of action, which allows for once-daily, or even less frequent, dosing.

Problems solved by technology

In spite of the success that has been achieved with certain β2 adrenergic receptor agonists, current agents possess less than desirable duration of action, potency, selectivity, and / or onset.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diamine Beta2 Adrenergic Receptor Agonists
  • Diamine Beta2 Adrenergic Receptor Agonists
  • Diamine Beta2 Adrenergic Receptor Agonists

Examples

Experimental program
Comparison scheme
Effect test

formulation example a

[0143] This example illustrates the preparation of a representative pharmaceutical composition for oral administration of a compound of this invention:

IngredientsQuantity per tablet, (mg)Active Ingredient1Lactose, spray-dried148Magnesium stearate2

[0144] The above ingredients are mixed and introduced into a hard-shell gelatin capsule.

formulation example b

[0145] This example illustrates the preparation of another representative pharmaceutical composition for oral administration of a compound of this invention:

IngredientsQuantity per tablet, (mg)Active Ingredient1Cornstarch50Lactose145Magnesium stearate5

[0146] The above ingredients are mixed intimately and pressed into single scored tablets.

formulation example c

[0147] This example illustrates the preparation of a representative pharmaceutical composition for oral administration of a compound of this invention.

[0148] An oral suspension is prepared having the following composition.

IngredientsActive Compound3mgFumaric acid0.5gSodium chloride2.0gMethyl paraben0.1gGranulated sugar25.5gSorbitol (70% solution)12.85gVeegum K (Vanderbilt Co.)1.0gFlavoring0.035mLColorings0.5mgDistilled waterq.s. to 100mL

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention provides novel β2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.

Description

FIELD OF THE INVENTION [0001] The invention is directed to novel β2 adrenergic receptor agonists. The invention is also directed to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds. BACKGROUND OF THE INVENTION [0002]β2 adrenergic receptor agonists are recognized as effective drugs for the treatment of pulmonary diseases such as asthma and chronic obstructive pulmonary disease (including chronic bronchitis and emphysema). β2 adrenergic receptor agonists are also useful for treating pre-term labor, and are potentially useful for treating neurological disorders and cardiac disorders. In spite of the success that has been achieved with certain β2 adrenergic receptor agonists, current agents possess less than desirable duration of action, potency, selectivity, and / or onset. Thus, there is a need for additional β2 adre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/47C07D215/00G01N33/53A61K31/137A61K31/16A61K31/4706C07C215/00C07D215/22C07D215/227
CPCC07D215/26C07D215/227A61P11/00A61P11/06A61P43/00
Inventor LINSELL, MARTIN S.
Owner THERAVANCE BIOPHARMA R&D IP LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com